Hoth Therapeutics Inc., of New York, entered a commercial evaluation sublicense and option agreement with the University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc., of Baltimore, for retinoic acid metabolism-blocking agents as treatments for dermatological conditions. Terms of the deal weren't disclosed.